

Nil

File No. FDC/MA/21/000195 ✓

Tele. No. : 011-23236965

Fax No. : 011-23236973

Government of India

Directorate General of Health Services
Central Drugs Standard Control Organization
(FDC Division)

FDA Bhawan, Kotla Road
New Delhi-110002

Dated:

04 OCT 2021

To,

M/s. Mascot Health Series Pvt. Ltd.,
Plot No. 79-80, Sector 6A, IIE SIDCUL,
Haridwar, Uttarakhand-249403.

Subject: Permission to conduct Phase III clinical trial with the FDC of Nortriptyline IP 10mg + Methylcobalamin IP 1500mcg + Pregabalin IP (SR) 75mg film coated bilayered tablets (Vide protocol no. MCR/CT/0721/02, version no. 00, dated: 02.06.2021)-regarding.

Dear Sir,

With reference to your online application submitted in Form CT-21 on dated 21.08.2021 please find enclosed herewith the "permission to conduct clinical trial study of new drug" bearing no. CT-06-163/2021 under the provision of Drugs and Cosmetics Act and Rules. The permission is subject to the conditions mentioned below.

Kindly acknowledge receipt to this letter and its enclosures.

Yours faithfully,

V.G.

(Dr. V. G. Somani)
Drugs Controller General (India)

CONDITIONS OF PERMISSION

- I. Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- II. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
 - i. Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
 - ii. Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- III. In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- IV. The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- V. Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

Permission no.: CT-06-163/2021

1. The Central Licencing Authority hereby permits **M/s. Mascot Health Series Pvt. Ltd., Plot No. 79-80, Sector 6A, IIE SIDCUL, Haridwar, Uttarakhand-249403, Telephone no. 01334-239039, Fax no. 01334-239039** to conduct clinical trial of the new drug or investigational new drug as per protocol number (**Vide protocol no. MCR/CT/0721/02, version no. 00, dated: 02.06.2021**) in the below mentioned clinical trial sites.
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date:

04 OCT 2021
Annexure:

Central Licencing Authority

Stamp
Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug:	Nortriptyline IP 10mg + Methylcobalamin IP 1500mcg + Pregabalin IP (SR) 75mg film coated bilayered tablets
Therapeutic class:	Anticonvulsant
Dosage form:	Film Coated Bilayered Tablets
Composition:	Nortriptyline IP 10mg + Methylcobalamin IP 1500mcg + Pregabalin IP (SR) 75mg film coated bilayered tablets
Indications:	Patients with diabetic peripheral neuropathic pain with coexistant vitamin B12 deficiency

Details of clinical trial site:

Names and address of clinical trial site:	As per annexure- A
Ethics committee details:	As per annexure- A
Name of principal investigator:	As per annexure- A

Permission no.: CT-06-163/2021

S. No.	Name of PI	Site Name	Ethics Committee Name, Address & EC registration No
1	Dr. Sunil M Jain	Total Diabetes Hormone Institute, A unit of Diabetes Thyroid Hormone Research Institute Pvt Ltd, BCM Health Island, PU4, Scheme 54, Near Bombay Hospital, Indore-452010 (Madhya Pradesh), India	EC of Diabetes Thyroid Hormone Research Institute, Diabetes Thyroid Hormone Research Institute, Total Diabetes Hormone Institute, Scheme 54, Near Bombay Hospital, Indore-452010, India ECR/409/Inst/MP/2013/RR-19
2	Dr. Amol Laxmanrao Dange	Lifepoint Multispeciality Hospital, 145/1, Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad, Pune-411057, Maharashtra, India.	Lifepoint Research – Ethics Committee, Lifepoint Multispeciality Hospital Pvt. Ltd., 145/1, Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad, Pune, Maharashtra-411057, India. ECR/751/Inst/MH/2015/RR-21
3	Dr. Prabhat Kumar Sharma	Maharaja Agrasen Superspeciality Hospital, Jaipur, Rajasthan	Institutional Ethics Committee, Maharaja Agrasen Superspeciality Hospital, Central Spine, Agrasen Aspatal Marg, Sector 7, Vidyadhar Nagar, Jaipur-302039, Rajasthan, India. ECR/1222/Inst/RJ/2019
4	Dr. Bongi Vivekanand	King George Hospital, Department of Endocrinology, Super speciality block, Maharanipectha, Vishakhapatnam 530002, Andhra Pradesh	IEC King George Hospital King George Hospital Maharanipectha Collector office junction Visakhapatnam Visakhapatnam Andhra Pradesh -530002 India ECR/197/Inst/KGH/2 013/RR-20
5	Dr. Raja Bhattacharya	Medical College and Hospital Kolkata 700073, West Bengal, India	Institutional Ethics Committee for Human Research Medical College, Kolkata Medical College, Kolkata 88, College Street Kolkata West Bengal-700073, India ECR/287/Inst/WB/2013/RR-19

Place: New Delhi

Date:

04 OCT 2021

Central Licencing Authority

Stamp

Dr. V. G. SOMANI
 Drugs Controller General (India)
 Dte. General of Health Services
 Ministry of Health and Family Welfare
 FDA Bhawan, Kotla Road, L.T.O.
 New Delhi-110002